By Stephen Nakrosis
Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.
The company said Tuesday that results from its Signal-AA trial demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata, while the results from its Signal-AD trial in atopic dermatitis demonstrated promising findings in Part A but didn't meet primary endpoint in Part B.
After the bell, the company's shares had fallen 66%, to trade at $8.20. The stock touched an all-time low of $8.24 on Nov. 16, 2023.
Jason Campagna, the chief medical officer of Q32 Bio, said the company was looking forward to advancing bempikibart as a potential treatment for alopecia areata, which causes hair loss.
Chief Executive Jodie Morrison said Q32 plans to conduct a review to better understand the results of the Signal-AD trial.
Bempikibart was observed to be safe and well tolerated across both trials, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 10, 2024 18:32 ET (23:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。